YMTX Stock Overview
Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding.
Yumanity Therapeutics, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.66|
|52 Week High||US$13.90|
|52 Week Low||US$0.95|
|1 Month Change||-5.68%|
|3 Month Change||38.35%|
|1 Year Change||-82.85%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-92.49%|
Recent News & Updates
|YMTX||US Biotechs||US Market|
Return vs Industry: YMTX underperformed the US Biotechs industry which returned -22.1% over the past year.
Return vs Market: YMTX underperformed the US Market which returned -11.6% over the past year.
|YMTX Average Weekly Movement||18.1%|
|Biotechs Industry Average Movement||12.5%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: YMTX is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 18% a week.
Volatility Over Time: YMTX's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson’s disease and related disorders of a-synuclein.
Yumanity Therapeutics, Inc. Fundamentals Summary
|YMTX fundamental statistics|
Is YMTX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|YMTX income statement (TTM)|
|Cost of Revenue||US$18.90m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-3.55|
|Net Profit Margin||-760.15%|
How did YMTX perform over the long term?See historical performance and comparison